The RESPImmun Faculty

	Katharina LEITHNER, MD, PhD Gluconeogenesis in tumor-promoting macrophages
Division of Pumonology, Department of Internal Medicine; Medical University of Graz, Auenbruggerplatz 15, A-8036 Graz; phone: +43-316-385 80631, fax: +43-316-385 13578, ✉ e-mail
websites: [RESPImmun] [MUG]
• Profile     • Curriculum vitae     • PhD students     • Grants     • Publications ⏬

List of publications:

• See ⏩ Fodok Med Uni Graz

10 most significant publications:

1. Lesko J, Triebl A, Stacher-Priehse E, Fink-Neuböck N, Lindenmann J, Smolle-Jüttner FM, Köfeler HC, Hrzenjak A, Olschewski H, Leithner K: Phospholipid dynamics in ex vivo lung cancer and normal lung explants Exp Mol Med, 2021; 53(1):​81–90.
2. Smolle E, Leko P, Stacher-Priehse E, Brcic L, El-Heliebi A, Hofmann L, Quehenberger F, Hrzenjak A, Popper HH, Olschewski H, Leithner K: Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer Mol Oncol, 2020; 14(11):​2853–2867.
3. Grasmann G, Smolle E, Olschewski H, Leithner K: Gluconeogenesis in cancer cells – Repurposing of a starvation-induced metabolic pathway? Biochim Biophys Acta Rev Cancer, 2019; 1872(1):​24–36.
4. Leithner K, Triebl A, Trötzmüller M, Hinteregger B, Leko P, Wieser BI, Grasmann G, Bertsch AL, Züllig T, Stacher E, Valli A, Prassl R, Olschewski A, Harris AL, Köfeler HC, Olschewski H, Hrzenjak A: The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells. Proc Natl Acad Sci USA, 2018; 115(24):​6225–6230.
5. Seidl C, Panzitt K, Bertsch A, Brcic L, Schein S, Mack M, Leithner K, Prinz F, Olschewski H, Kornmueller K, Hrzenjak A: MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Lett, 2020; 469:​266–276.
6. Leithner K, Hirschmugl B, Li Y, Tang B, Papp R, Nagaraj C, Stacher E, Stiegler P, Lindenmann J, Olschewski A, Olschewski H, Hrzenjak A: TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers. PLos One, 2016; 11(6):​e0157453.
7. Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, Olschewski H, Hrzenjak A: Panobinostat reduces hypoxia-induced cisplatin resistance of non-small-cell lung carcinoma cells via HIF-1α destabilization. Mol Cancer, 2015; 14:4.
8. Leithner K, Hrzenjak A, Trötzmüller M, Moustafa T, Köfeler HC, Wohlkoenig C, Stacher E, Lindenmann J, Harris AL, Olschewski A, Olschewski H: PCK2 activation mediates an adaptive response to glucose depletion in lung cancer. Oncogene, 2015; 34(8):​1044–1050.
9. Leithner K, Wohlkoenig C, Stacher E, Lindenmann J, Hofmann NA, Gallé B, Guelly C, Quehenberger F, Stiegler P, Smolle-Jüttner FM, Philipsen S, Popper HH, Hrzenjak A, Olschewski A, Olschewski H: Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model – role of tumor stroma cells. BMC Cancer, 2014; 14:40.
10. Wohlkoenig C, Leithner K, Deutsch A, Hrzenjak A, Olschewski A, Olschewski H: Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. Cancer Lett, 2011; 308(2):​134–143.

31.08.2021 RESPImmun · Doctoral Programme “Immune Modulation in Respiratory Diseases”